Champions Oncology, Inc.
CSBR
$7.63
$0.222.97%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.54% | 19.03% | 7.19% | -1.96% | -6.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.54% | 19.03% | 7.19% | -1.96% | -6.90% |
| Cost of Revenue | -3.45% | -3.80% | 0.89% | -4.56% | -0.44% |
| Gross Profit | 37.59% | 53.15% | 16.15% | 1.53% | -14.73% |
| SG&A Expenses | -6.87% | -8.79% | -5.63% | -0.49% | 5.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.72% | -10.61% | -8.07% | -7.93% | -2.13% |
| Operating Income | 170.03% | 176.43% | 95.94% | 54.76% | -55.54% |
| Income Before Tax | 163.32% | 166.28% | 93.35% | 54.22% | -38.73% |
| Income Tax Expenses | -138.71% | -137.14% | -150.00% | -148.10% | -145.59% |
| Earnings from Continuing Operations | 164.61% | 166.07% | 93.79% | 55.20% | -36.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 164.61% | 166.07% | 93.79% | 55.20% | -36.38% |
| EBIT | 170.03% | 176.43% | 95.94% | 54.76% | -55.54% |
| EBITDA | 228.36% | 221.01% | 120.76% | 76.77% | -78.36% |
| EPS Basic | 164.17% | 165.46% | 93.84% | 55.20% | -36.56% |
| Normalized Basic EPS | 171.07% | 176.55% | 97.72% | 55.15% | -54.33% |
| EPS Diluted | 158.23% | 160.46% | 91.59% | 53.34% | -36.37% |
| Normalized Diluted EPS | 167.16% | 173.51% | 97.01% | 54.53% | -54.33% |
| Average Basic Shares Outstanding | 0.83% | 0.60% | 0.47% | 0.24% | 0.05% |
| Average Diluted Shares Outstanding | 3.67% | 3.44% | 2.08% | 1.06% | 0.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |